# Pharmacokinetic and pharmacodynamic characterization of gepotidacin against Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh infection model

## TL;DR

This study evaluates how well the new antibiotic gepotidacin works against E. coli and K. pneumoniae in a mouse model, to support its use in treating urinary tract infections.

## Contribution

The study provides in vivo PK/PD data for gepotidacin against multiple E. coli and K. pneumoniae isolates in a neutropenic mouse model.

## Key findings

- The median fAUC/MIC ratio for effective treatment was 13.
- PK/PD targets were successfully applied to urine concentrations for uUTI treatment.
- Further validation is needed for broader application in cystitis.

## Abstract

Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic developed for the treatment of uncomplicated gonorrhea and uncomplicated urinary tract infections (uUTIs). To support uUTI, in vivo pharmacokinetics (PK)/pharmacodynamics (PD) studies have been conducted in the murine neutropenic thigh infection model evaluating gepotidacin against 17 isolates of Escherichia coli and 7 isolates of Klebsiella pneumoniae having MICs of 0.25 to 16 µg/mL. Exposure data were fit using a population PK model, and efficacy data were fit with an inhibitory effect sigmoid Imax model using free-drug area under the concentration-time curve (fAUC)/MIC as the primary index. The ratios associated with response were determined for each isolate, and the median fAUC/MIC (excluding strains with <1-log of growth from baseline) was 13. To retain the data for all isolates, an exploratory analysis was conducted using different criteria to determine the target for strains with <1-log of growth (6 of the 24 strains tested). While the median fAUC/MIC was similar regardless of the criteria used, this analysis highlights the importance of critically reviewing PK/PD data for trends related to isolate characteristics and/or individual study outputs. As previously reported, the systemic targets determined from PK/PD studies were applied to urine concentrations for probability of target attainment analyses, which led to successful clinical trials and regulatory approval for gepotidacin in the treatment of uUTI. However, further work is needed to confirm the translational validity of these approaches on a broader scale and their application in establishing PK/PD targets for cystitis.